Product overview with focus on rare and special diseases.
AOP Orphan's focus is on rare and special diseases. The portfolio comprises products in the following therapeutic areas: HematoOncology, Cardiology & Pulmonology, Neurology and Metabolic Disorders and Intensive Care. AOP Orphan’s strategic goal is to constantly deliver new treatment options with respect to rare and special diseases.
Adepend is used as part of a comprehensive programme of treatment against alcoholism to reduce the risk of relapse, as support treatment in abstinence and to reduce the craving for alcohol.
Adepend is used as part of a comprehensive treatment programme against alcoholism to reduce the risk of relapse, as support treatment in abstinence and to reduce the craving for alcohol.
Anagrelide AOP is used to reduce the number of platelets in patients with essential thrombocythaemia.
Argipressin AOP is used to treat diabetes insipidus and bleeding from enlarged veins in the oesophagus.
BESREMi® is indicated as monotherapy in adults for the treatment of Polycythaemia Vera without symptomatic splenomegaly.
"Argipressin based vasopressor indicated for the treatment of catecholamine refractory hypotension following septic shock in patients older than 18 years. A catecholamine refractory/resistant hypotension is present if the mean arterial blood pressure cannot be stabilized to >65 mmHg despite adequate volume substitution and application of catecholamines."
Empressin® is used for the treatment of catecholamine refractory hypotension following septic shock in patients older than 18 years. A catecholamine refractory hypotension is present if the mean arterial blood pressur cannot be stabilized to 65 – 75 mmHg despite adequate volume substitution and application of catecholamines.
Esmocard® is indicated for supraventricular tachycardia and for the rapid control of the ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short-acting agent is desirable.
"Esmolol hydrochloride is indicated for supraventricular tachycardia (except for pre-excitation syndromes) and for the rapid control of the ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short-acting agent is desirable. Esmolol hydrochloride is also indicated for tachycardia and hypertension occurring in the perioperative phase and non-compensatory sinus tachycardia where, in the physician’s judgement the rapid heart rate requires specific intervention."
Esmolol® is indicated for supraventricular tachycardia and for the rapid control of the ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short-acting agent is desirable.
Naloxone hydrochloride is for complete or partial reversal of CNS and especially respiratory depression, caused by natural or synthetic opioids.
Naltrexone AOP is for use as an additional therapy within a comprehensive treatment program including psychological guidance for detoxified patients who have been opioid-dependent.
"Complete or partial reversal of CNS depressive effects, especially respiratory depression, caused by natural or synthetic opioids and partial agonist/antagonist opioids. It is also used to diagnose a suspected acute opioid overdose or intoxication or to reduce the effect of opioids, which were used for anesthesia in operations."
Tetrabenazine is used for the treatment of diseases causing jerky, irregular, uncontrollable movements (hyperkinetic motor disorders with Huntington’s chorea).